THE RISK FACTORS AND SPECIFIC FEATURES OF OSTEOPENIC SYNDROME IN PATIENTS WITH CHRONIC NON-INFECTIOUS DISEASES

Objective: to analyze the risk factors (RFs) of osteoporosis (OP), the risk of OP-related fractures, the specific features of osteopenic syndrome in patients with chronic non-infectious diseases (CNID) (coronary heart disease (CHD), hypertension, chronic obstructive pulmonary disease (COPD), and asthma).
Materials and methods. The investigation enrolled 377 patients (mean age 55.3 ± 1.6 years) with CNID and 221 persons (mean age, 53.2 ± 1.3 years) who formed a control group. According to the nosological entity, the patients were divided as follows: Group 1 included 84 patients with CHD and hypertension; Group 2 comprised 99 hypertensive patients; Group 3 consisted of 70 patients with COPD; and Group 4 included 124 asthmatic patients. The examinees of all the groups were matched for age, gender, and body mass index. The investigation excluded patients with functional class IV chronic heart failure, continuous atrial fibrillation, heart valve disease, or myocardial noncoronarogenic diseases and those with other diseases and conditions that could have an independent impact on bone metabolism. Prior to the examination, the patients had received no specific therapy for the prevention and treatment of OP. RFs for OP were assessed using the one-minute test recommended by the International OP Foundation (2008); 10-year risk for OP-related fractures were calculated applying the FRAX computer program in accordance with the guidelines of the International OP Association and the World Health Organization (WHO, 2008). To investigate bone mineral density (BMD), bioenergy X-ray densitometry of the lumbar spine and proximal femur was carried out by means of a Lunar DPX apparatus (USA). The results were assessed using the t-test in standard deviations (SD) from the peak bone mass according to the WHO guidelines.
Results. The RFs of OP were more frequently recorded in the patients with CNID than in the healthy individuals. RFs, such as smoking, low physical activity, and low-energy fractures, were most common in the patients with cardiovascular disease or COPD. The frequent use of glucocorticoid therapy was also an important RF in the patients with COPD. CHID considerably increased the risk of fractures in the succeeding 10 years after disease onset. The high risk of fractures, those of the proximal femur in particular, provides a rationale for the need for timely antiosteoporotic therapy in the majority of patients with CNID. The performed investigation demonstrated that the BMD values in the patients with CNID corresponded, on the average, to the osteopenia criteria; the lowest BMD values were recorded in the patients with COPD and associated cardiovascular disease. The severe course of osteopenic syndrome (a BMD decrease that was diagnostically significant for OP concurrent with fractures was observed in one-third of patients with CNID. The patients with cardiovascular disease or COPD showed a high incidence and degree of OP, which allows these diseases to be considered as a RF for decreased BMD. The long-term uncontrolled course of disease, the degree of organ and functional disorders in the patients with CNID, and concomitant use of glucocorticoid therapy contribute to a reduction in BMD.
Conclusion. RFs for OP were identified in the majority of patients with CNID. The high risk of fractures due to an obvious BMD decrease in patients with CNID requires timely diagnosis, treatment, and prevention of osteopenia.

1. Ensrud K.E., Thompson D.E., Cauley J.A. et al. Prevalent vertebral deformities predict mortality and hospitalization in older women with low bone mass. Fracture Intervention Trial Research Group. J Am Geriatr Soc 2000;48(3):241–9.

2. Hasserius R., Karlsson M.K., Nilsson B.E. et al. Prevalent vertebral deformities predict increased mortality and increased fracture rate in both men and women: a 10-year populationbased study of 598 individuals from the Swedish cohort in the European Vertebral Osteoporosis Study. Osteoporosis Int 2003;14(1):61–8.

3. Jalava T., Sarna S., Pylkkänen L. et al. Association between vertebral fracture and increased mortality in osteoporotic patients. J Bone Miner Res 2003;18(7):1254–60.

4. Naves M., Diaz-Lopez J.B., Gomez C. et al. The effect of vertebral fracture as a risk factor for osteoporotic fracture and mortality in a Spanish population. Osteoporosis Int 2003;14(6):520–4.

5. Tankó L.B., Christiansen C., Cox D.A. et al. Relationship between osteoporosis and cardiovascular disease in postmenopausal women. J Bone Miner Res 2005;20(11): 1912–20.

6. Tankó L.B., Bagger Y.Z., Christiansen С. Low bone mineral density in the hip as a marker of advanced atherosclerosis in elderly women. Calcif Tissue Int 2003;73(1):15–20.

7. Uyama O., Yoshimoto Y., Yamamoto Y., Kawai A. Bone changes and carotid atherosclerosis in postmenopausal women. Stroke 1997;28(9):1730–2.

8. von der Recke P., Hansen M.A., Hassager C. The association between low bone mass at the menopause and cardiovascular mortality. Am J Med 1999;106(3):273–8.

9. Marcovitz P.A., Tran H.H., Franklin B.A. et al. Usefulness of bone mineral density to predict significant coronary artery disease. Am J Cardiol 2005;96(8):1059–63.

10. Оконечникова Н.С., Болотнова Т.В. Клинико-функциональные характеристики больных пожилого возраста с ассоциированной патологией: артериальной гипертензией, ишемической болезнью сердца и хронической обструктивной болезнью легких. Медицинская наука и образование Урала 2012;13(1):31–3. [Okonechnikova N.S., Bolotnova T.V. Clinical and functional properties of elderly patients with associated pathology: arterial hypertension, atherosclerotic heart disease and chronic obstructive pulmonary disease. Meditsinskaya nauka i obrazovanie Urala = Medical Science and Education of Urals 2012;13(1):31–3. (In Russ.)].

11. Stimpel M., Jee W.S., Ma Y. et al. Impact of antihypertensive therapy on postmenopausal osteoporosis: effects of the angiotensin converting enzyme inhibitor moexipril, 17 beta-estradiol and their combination on the ovariectomy-induced cancellous bone loss in young rats. J Hypertens 1995; 13 (12 Pt 2):1852–6.

12. Глобальная стратегия диагностики, лечения и профилактики хронической обструктивной болезни легких (пересмотр 2014 г.). Пер. с англ. Под ред. А.С. Белевского. М.: Российское респираторное общество, 2014. [The global strategy for diagnosis, management and prevention of chronic obstructive pulmonary disease (review of 2014). Transl. from English. Ed. by A.S. Belevskiy. Мoscow: Rossiyskoe Respiratornoe Obshchestvo, 2014. (In Russ.)].

13. Soriano J.B., Visick G.T., Muellerova H. et al. Patterns of comorbidities in newly diagnosed COPD and asthma in primary care. Chest 2005;128(4):2099–107.

14. Fabbri L.M., Luppi F., Beghe B., Rabe K.F. Complex chronic comorbidities of COPD. Eur Respir J 2008;31(1):204–12.

15. Madsen H., Brixen K., Hallas J. Screening, prevention and treatment of osteoporosis in patients with chronic obstructive pulmonary disease – a population-based database study. Clin Respir J 2010;4(1):22–9.

16. Incalzi R.A., Caradonna P., Ranieri P. et al. Correlates of osteoporosis in chronic obstructive pulmonary disease. Respir Med 2000;94(11):1079–84.

17. Платицына Н.Г., Болотнова Т.В. Остеопороз и хроническая обструктивная болезнь легких: факторы риска, особенности сочетанного течения. Врач 2014;(11): 48–50. [Platitsyna N.G., Bolotnova T.V. Osteoporosis and chronic obstructive pulmonary disease: risk factors, peculiarities of combined diseases. Vrach = Physician 2014;(11):48–50. (In Russ.)].

18. Баранова И.А. Остеопороз в практике пульмонолога. Фарматека 2013;(s5–13): 14–20. [Baranova I.A. Osteoporosis in pulmonologist’s practice. Farmateka = Pharmateca 2013;(s5–13):14–20. (In Russ.)].

19. Некрасова М.Р., Суплотова Л.А., Давыдова Л.И. и др. Остеопенический синдром при эндокринных заболеваниях в Западной Сибири. Остеопороз и остеопатии 2005;(2):14–8. [Nekrasova M.R., Suplotova L.A., Davydova L.I. et al. Osteopenic syndrome at endocrine diseases in Western Siberia. Osteoporoz i osteopatii = Osteoporosis and Osteopathy 2005;(2):14–8. (In Russ.)].

20. Минутный тест для определения риска развития остеопороза. Российская ассоциация по остеопорозу. Информационный портал. Доступно по ссылке: http://www.osteoporoz.ru/content/ view/1551/70/. [The minute test for determination of osteoporosis development risk. Russian Association of Osteoporosis. Information portal. Available at: http://www.osteoporoz.ru/content/ view/1551/70/. (In Russ.)].

21. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser 1994;843:1–129.

22. Лесняк О.М., Беневоленская Л.И. Остеопороз: Диагностика, профилактика и лечение. Клинические рекомендации. 2-е изд. М.: ГЭОТАР-Медиа, 2009. [Lesnyak O.M., Benevolenskaya L.I. Osteoporosis: Diagnosis, prevention and treatment. Clinical guidelines. 2nd edn. Moscow: GEOTAR-Media, 2009. (In Russ.)]. 23. Рожинская Л.Я. Остеопороз: актуальный взгляд. Фарматека 2012;(s1–12): 54–62. [Rozhinskaya L.Ya. Osteoporosis: current opinion. Farmateka = Pharmateca (In Russ.)].